AKT1 and respiratory tract infectious disorder: We hypothesize that enhancement of NO production via another method (e.g., targeting the Akt pathway as with SC79 or artificial NO donor compounds), may be beneficial to reducing respiratory infections with gram-negative bacteria, though further research is needed to test this in more detail.